IP Library Patent Application 17236008
Patent Application
App. No. 17/236,008

ORAL DISSOLVABLE FILM WITH HIGH LOAD OF POLYMERIC BINDER

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/236,008
Abstract

The present invention relates to an oral dissolvable film (ODF), methods of orally administering the same, and methods of manufacturing the same. The ODF includes a high load of binder. Such an ODF, containing a high load of binder, can achieve the requisite physical and performance characteristics and can be manufactured on a commercial scale, while demonstrating that the ODF is safe and effective to consumers for its intended use. This also includes formulating and configuring the ODF to deliver the API as desired, via, e.g., enteral, transmucosal, sublingual, and/or buccal, when the administration is oral.

Claims (31)

1 . An oral dissolvable film comprising:

(a) a film matrix comprising binders (i) and (ii):

(i) Kollicoat® Protect, Kollicoat® IR, or a combination thereof;

(ii) at least one additional binder;

(b) solvent comprising water;

(c) an active pharmaceutical ingredient (API); and

(d) pharmaceutically acceptable excipient comprising at least one of a filler, preservative, sweetening agent, co-solvent, plasticizer, flavoring agent, taste masking agent, colorant, anti-caking agent, coating agent, emulsifier, solubilizing agent, lipid, humectant, thickening agent, lubricant, adsorbent, suspending agent, disintegrating agent, permeation enhancer, saliva stimulating agent, release modifier, adjuvant, fragrance, surfactant, pH adjusting agent, buffering agent, stabilizer, and antioxidant;

wherein,

the binders in (a)(i) and (a)(ii) are present in an aggregate amount of at least 30 wt. % of the oral dissolvable film; and

the one or more binders in (a)(i) are present in an aggregate amount of at least 25 wt. % of the oral dissolvable film.

2 . The oral dissolvable film of claim 1 , wherein the at least one additional binder in (ii) is selected from the group consisting of sodium carboxymethyl cellulose (Na-CMC), hydroxypropyl methyl cellulose E3, hydroxypropyl methyl cellulose K3, hydroxypropyl methyl cellulose E5, hydroxypropyl methyl cellulose E15, methyl cellulose A3, methyl cellulose A6, methyl cellulose A15, hydroxypropyl cellulose, pullalan, sodium alginate, ethyl cellulose, lactose, Kollidon® K90, Kollidon® VA64, Kollidon® 12 PF, Kollidon® 17 PF, Kollidon® 25 PF, Kollidon® 30 PF, Kollidon® SR, polyvinyl alcohol, Soluplus®, Eudragit® RL100, Eudragit® EP O, chitosan, carrageenan, carbomer, xanthan gum, starch, maltodextrin, gelatin, microcrystalline cellulose, hydroxyethylcellulose, and combinations thereof.

3 . The oral dissolvable film of claim 1 , having a drug load of API of at least 25 wt. %.

4 . The oral dissolvable film of claim 1 , having a drug load of API of up to 45 wt. %.

5 . The oral dissolvable film of claim 1 , having a drug load of API of 30-40 wt. %.

6 . The oral dissolvable film of claim 1 , wherein the one or more binders in (i) are present in an aggregate amount of at least 30 wt. % of the oral dissolvable film.

7 . The oral dissolvable film of claim 1 , having a weight ratio of binder to API of at least 0.8.

8 . The oral dissolvable film of claim 1 , having a weight ratio of binder to API of 0.8 to 1.4.

9 . The oral dissolvable film of claim 1 , wherein the aggregate amount of binder and API is present in at least 59 wt. % of the oral dissolvable film.

10 . The oral dissolvable film of claim 1 , wherein the aggregate amount of binder and API is present in 65±6 wt. % of the oral dissolvable film.

11 . The oral dissolvable film of claim 1 , having a thickness of 0.2-0.7 mm.

12 . The oral dissolvable film of claim 1 , which is in a unit dosage form and having a mass of 180-260 mg.

13 . The oral dissolvable film of claim 1 , having a density of 0.65-0.85 g/cm 3 .

14 . The oral dissolvable film of claim 1 , having a dissolution of at least 90 wt. % at 5 minutes, as measured using a USP apparatus of 1 basket, 0.01 N HCl media, volume of 900-ml at a temperature of 37±0.5° C. mixed at 100 RPM that is sampled at 5, 10, 15, 30, 45, and 60 min.

15 . The oral dissolvable film of claim 1 , having a dissolution of 100 wt. % at 10 minutes, as measured using a USP apparatus of 1 basket, 0.01 N HCl media, volume of 900-ml at a temperature of 37±0.5° C. mixed at 100 RPM that is sampled at 5, 10, 15, 30, 45, and 60 min.

16 . The oral dissolvable film of claim 1 , exhibiting a high stability such that at least 90 wt. % of API remains in the oral dissolvable film, under accelerated stability conditions of 40±2° C., relative humidity (RH) 75±5%, over a period of time of >6 months.

17 . The oral dissolvable film of claim 1 , exhibiting a high stability such that at least 90 wt. % of API remains in the oral dissolvable film, under stability conditions of 25±2° C., relative humidity (RH) 60±5%, over a period of time of >6 months.

18 . The oral dissolvable film of claim 1 ,

substantially devoid of a carminative substance, such that any carminative substance present therein is present in less than 0.1 wt. %;

substantially devoid of an antifoaming agent, such that any antifoaming agent present therein is present in less than 0.1 wt. %; and

substantially devoid of a substances that lowers the surface tension of gas bubbles, such that any substances that lowers the surface tension present in less than 0.1 wt. %.

19 . The oral dissolvable film of claim 1 , which has a loss on drying (LOD) of 10±5 wt. %.

Assignments (5)
LIEN Recorded Jan 28, 2025
From: CURE PHARMACEUTICAL, INC.
To: CUREX PHARMACEUTICAL MEXICO S.A.P.I. DE C.V.
Reel/Frame 070027/0201 →
CHANGE OF NAME Recorded Jul 17, 2023
From: TF TECH VENTURES, INC.
To: CURE PHARMACEUTICAL, INC.
Reel/Frame 064286/0450 →
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY NAME WHICH SHOULD READ TF TECH VENTURES, INC. AND NOT TF TECH VENTURES PREVIOUSLY RECORDED AT REEL: 060598 FRAME: 0016. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jul 12, 2023
From: CURE PHARMACEUTICAL CORPORATION
To: TF TECH VENTURES, INC.
Reel/Frame 064256/0361 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 22, 2022
From: CURE PHARMACEUTICAL CORPORATION
To: TF TECH VENTURES
Reel/Frame 060598/0016 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 10, 2022
From: ESPINOZA, MARIBEL; GIGI, VERED; PIRJANIAN, ARMEN
To: CURE PHARMACEUTICAL CORPORATION
Reel/Frame 059884/0986 →